Synonyms: compound 2 [PMID: 30532965] | compound 3 [PMID: 26301626] | GSK-2292767
Compound class:
Synthetic organic
Comment: GSK2292767 is a selective PI3Kδ inhibitor that was developed as a back-up compound to clinical lead nemiralisib (GSK2269557) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
GSK2292767 was progressed to Phase 1 evaluation (NCT03045887) with the intended indication being asthma. In early 2020 GSK opted to terminate GSK2292767 development in respiratory diseases. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03045887 | Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes | Phase 1 Interventional | GlaxoSmithKline |